Abstract
Tyrosine kinase receptors have been shown to play an important role in epithelial thyroid tumor growth and angiogenesis. Thyroid cancers commonly present oncogene mutations involved in MAPK kinase pathway like BRAF and RET; they are also frequently dependent from VEGF stimuli. Preliminary clinical experiences suggest a promising role of sunitinib (a tyrosine kinase inhibitor) for the treatment of advanced thyroid cancers. This chapter deals with the available data on the effect of sunitinib in the treatment of metastatic, radioiodine refractory thyroid cancers.
Keywords: AKT/PI3K pathways, follicular thyroid cancer, hypothyroidism, levothyroxine, macrocytosis, MAPK kinase, metastasis, neoangiogenesis, papillary thyroid cancer, PDGFR-ß, PDGFR-α, radioactive iodine, refractory DTC, RET, RET/PTC, sunitinib, Thyroid cancer, TSH suppressive, tyrosin-kinase inhibitor, VEGF, VEGFR.
Related Journals
Related Books
A Journey Through Water: A Scientific Exploration of The Most Anomalous Liquid on Earth
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications Volume 1 (Revised Edition)
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis